Vonozan 20 

Presentation: Each film-coated tablet contains Vonoprazan Fumarate INN equivalent to Vonoprazan 20 mg. It is usually available in blister packs. 

Indications: Vonozan (Vonoprazan) is a potassium-competitive acid blocker (P-CAB) indicated for:

• Treatment of gastric ulcer.
• Treatment of duodenal ulcer.
• Treatment of reflux esophagitis (erosive GERD).
• Maintenance therapy to prevent recurrence or relapse of reflux esophagitis in patients with repeated occurrences.
• Prevention of recurrent gastric or duodenal ulcer associated with low-dose aspirin administration.
• Prevention of recurrent gastric or duodenal ulcer associated with NSAID administration.
• Adjunct to Helicobacter pylori eradication in specific conditions (gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, post-endoscopic resection of earlygastric cancer, or H. pylori gastritis), usually in combination with antibiotics like amoxicillin and/or clarithromycin.

Dosage and Administration: The usual adult dose is 20 mg once daily for gastric ulcer (up to 8 weeks) and duodenal ulcer (up to 6 weeks). For reflux esophagitis, the usual dose is 20 mg once daily for up to 4 weeks, which may be extended to 8 weeks if needed. For maintenance therapy of reflux esophagitis, the dose is 10 mg once daily, potentially increased to 20 mg if efficacy is inadequate. For preventing recurrence of ulcers with low-dose aspirin or NSAIDs, the dose is 10 mg once daily. For H. pylori eradication, it's typically 20 mg twice daily for 7 days with specific antibiotics.

Vonozan can be taken without regard to food. Follow your physician's instructions precisely.

Side Effects: Common side effects reported with Vonozan may include diarrhea, constipation, nausea, abdominal distension, and rash. Less common side effects can include drug hypersensitivity reactions (including anaphylactic shock), urticaria, hepatotoxicity, and jaundice.

Precautions: Vonozan is contraindicated in patients with known hypersensitivity to vonoprazan or any excipients and in patients receiving atazanavir sulphate, nelfinavir, or rilpivirine hydrochloride. Exercise caution in patients with renal disorders, as excretion of vonoprazan may be delayed, potentially increasing blood concentrations. Hepatic impairment may also require careful administration.

Use in Pregnancy and Lactation: Vonozan should be used during pregnancy only if the expected benefit outweighs the potential risk. It is advisable to avoid administering Vonozan to nursing mothers; if essential, breastfeeding should be discontinued.

Storage: Store below 30°C in a dry place, protected from light. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.